Vitamin E Acetate is the Primary Culprit
The answer is (c) vitamin E acetate. Vaping tetrahydrocannabinol (THC)-associated lung injury (EVALI) is strongly and specifically linked to vitamin E acetate used as an additive or diluent in THC-containing vaping products.
The Evidence Base
The CDC and FDA investigations during the 2019 EVALI outbreak identified vitamin E acetate (VEA) as the primary chemical of concern in THC-containing vaping products. Approximately 50% of THC-containing products examined contained VEA 1. This association is not merely correlative—the mechanism of injury has been elucidated through multiple research pathways.
Mechanisms of Toxicity
Direct cellular damage occurs through multiple pathways:
- VEA and CBD oil adhere to and accumulate on airway epithelial surfaces, causing dramatic increases in cell death after just 3 days of exposure 2
- Cellular uptake of VEA-containing condensates causes elevated metabolic stress and increased cell death rates in human bronchial epithelial cultures 2
- Proteomic analysis reveals increases in xenobiotic enzymes, oxidative stress markers, and cell death indicators 2
Thermal decomposition produces toxic compounds:
- When vaped at temperatures exceeding 430°C (range 375-569°C), VEA decomposes into toxic products including duroquinone, 1-pristene, and durohydroquinone monoacetate 3
- Under "dry hit" conditions (high temperatures at low e-liquid levels), VEA can produce ketene—a respiratory poison—at acutely toxic levels reaching up to 30 ppm in the lungs 4
- THC and VEA form a hydrogen-bonded complex that persists in aerosols, potentially affecting lung deposition and toxicity 1
Why Not the Other Options?
Liquefied paraffin (mineral oil): Not implicated in EVALI outbreak investigations
Magnesium silicate (talc): Associated with intravenous drug use complications, not vaping-related lung injury
Volatile organic compounds: While present in cannabis and vaping products 5, they are not the primary causative agent identified in EVALI cases
Clinical Implications
The EVALI outbreak resulted in 2,409 hospitalized cases and 52 deaths as of December 2019 6. The severity is underscored by rapid deterioration patterns: median time to rehospitalization was 4 days and median time to death after discharge was 3 days 6.
Key risk factors for worse outcomes include:
- Chronic cardiac disease
- Chronic pulmonary disease (COPD, obstructive sleep apnea)
- Diabetes
- Increasing age 6
This remains an ongoing public health crisis, with cases continuing to occur even in patients using nicotine-only products, though THC-containing products with VEA remain the primary concern 7.